Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

BCR fused ABL kinase is the critical driving oncogene for chronic myeloid leukemia (CML) and has been extensively studied as the drug discovery target in the past decade. The successful introduction of tyrosine kinase inhibitors (TKI) such as Imatinib, Dasatinib and Bosutinib has greatly improved th...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Biol Ther
المؤلفون الرئيسيون: Wu, Jiaxin, Wang, Aoli, Li, Xixiang, Chen, Cheng, Qi, Ziping, Hu, Chen, Wang, Wenliang, Wu, Hong, Huang, Tao, Zhao, Ming, Wang, Wenchao, Hu, Zhenquan, Liu, Qingwang, Wang, Beilei, Wang, Li, Li, Lili, Ge, Jian, Ren, Tao, Xia, Ruixiang, Liu, Jing, Liu, Qingsong
التنسيق: Artigo
اللغة:Inglês
منشور في: Taylor & Francis 2019
الموضوعات:
Research Paper
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606039/
https://ncbi.nlm.nih.gov/pubmed/30894066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1579958
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة